目的:探讨原发性阴道肠型腺癌（PVAIT）的临床诊治要点。方法:收集2015年1月至2019年12月中国医学科学院北京协和医学院肿瘤医院诊治的2例PVAIT患者的临床病理资料，并回顾分析相关文献。结果:2例患者均为早期病变，病灶局限，结合病理特征及影像学检查排除转移性癌，明确诊断为PVAIT。2例PVAIT患者中，1例患者行根治性手术治疗，术后同步放化疗，目前已随访43个月无复发；1例患者化疗后9个月肿瘤复发，复发后未规范治疗，发病48个月进展至Ⅳ期。结论:PVAIT临床罕见，需依靠病理及影像学检查与肠道转移性腺癌鉴别。治疗上应注重个体化，早期、病灶局限者首选手术治疗。

Background The aim of the study is to investigate the clinical features, treatments, and prognosis of stage 1 embryonal rhabdomyosarcoma of the female genital tract. Methods A retrospective analysis was performed on nine cases of stage 1 embryonal rhabdomyosarcoma of the female genital tract. Clinical characteristics, treatments, recurrence, and prognosis were analyzed. Results Of the nine patients with embryonal rhabdomyosarcoma, three originated from the vagina and six from the cervix. For the eight patients who initially received surgery, the median survival time was 88 months. As for the six patients that received adjuvant chemotherapy, five of them who received six or more cycles of treatment achieved tumor-free survival and the survival time ranged from 9 to 228 months. The remaining patient, who declined further treatment after two cycles of chemotherapy, relapsed 11 months following the surgery and died 3 months later. Out of the nine patients, only one was initially treated with chemotherapy, and achieved complete remission, but relapsed 21 months later. After a combination of surgery and chemotherapy, this patient remained tumor-free for total of 117 months. Conclusions Patients with early stage embryonal rhabdomyosarcoma of the female genital tract have good prognosis, and the combination of surgery and chemotherapy can lead to better outcomes.

OBJECTIVE:To investigate the clinical features, treatments and prognostic factors of rhabdomyosarcoma(RMS)in the female genital tract.METHODS:A retrospective analysis was performed on 13 cases of RMS in the female genital tract. Clinical characteristics, treatments and prognosis were compared and analyzed statistically.RESULTS:The median age was 21.0 years(range, 6 to 54 years). There were 6 cases vaginal RMS and 7 cases cervical RMS, included 11 cases of embryonal RMS(ERMS)and 2 cases of alveolar RMS(ARMS). According to the Federation International of Gynecology and Obstetrics(FIGO)staging system, there were 6 cases of stage Ⅰ , 3 cases of stage Ⅱ, 1 case of stage Ⅲ and 3 cases of stage Ⅳ, the median survival time were respectively 112.5, 153.0, 9.0 and 3.5 months. According to the Intergroup Rhabdomyosarcom Study Group(IRSG)staging system, there were 10 cases of stage Ⅰ and 3 cases of the stage Ⅳ, and their median survival time were respectively 112.5 and 3.5 months. Nine patients received surgery and the median survival time was 108.0 months(range, 9 to 228 months), 6 of them received chemotherapy after surgery and the median survival time was 152.0 months(range, 9 to 228 months), the other 3 cases did not receive any therapy after surgery and the median survival time was 25.0 months(range, 9 to 108 months). Four patients did not receive surgery and the median survival time was 6.3 months(range, 1 to 117 months). There were 2 cases received combined treatment included radiotherapy and the survival time were respectively 4 and 198 months. There were 8 cases who was survival without disease and 5 cases died of cancer. The median survival time in 13 patients was 25.0 months(range, 1 to 228 months)and the 5-year overall survival rate was 58.6%.CONCLUSIONS:The prognosis of early stage of RMS in the female genital tract is good. While, the prognosis of advanced stage is poor. The standard treatment strategy is combination of surgery and chemotherapy, whether radiotherapy could improve the prognosis still need further study.

Objective To evaluate the value of MRI for patients with cervical carcinoma.Methods 72 patients with cervical carcinoma who were treated in our hospital from Jan 2008 to Mar 2010 were included in the study.All patients were diagnosed as cervical carcinoma by biopsy.Before 2 weeks of operation,all of them took MRI including pelvic and abdomen.70 cases received pelvic lymph node dissection and radical hysterectomy,2 cases received cold knife cone cutting operation.The MRI was evaluated by comparing pathological results with preoperative MRI.Results A total of 72 women were included in this study.Of all,2 cases with CIN,61 cases with squamous cell carcinoma(84.7%),6 cases with adenocarcinoma(8.3%),1 case with adenosquamous carcinoma(1.4%) and 2 cases with small cell carcinoma (2.8%).In all of the patients,4 cases were staged as beforeⅠ_B,without MRI-confirmed cervical tumor.And there were 39 cases ofⅠ_(B1),17 cases ofⅠ_(B1),11 cases ofⅡ_A,and 17 cases ofⅡ_B.Sensitivity and specificity of MRI in the diagnosis of lymph node metastasis,parametrial involvement and vaginal extension,deep stromal invasion were 85.71% vs 84.92%,100%vs 97.01%,37.5%vs 89.47%and 96.15%vs 80.00%,respectively.2 patients with endogenous cervical cancer which were difficult to be confirmed preoperatively were indicated by MRI that the lesions invaded muscle layer.Conclusion MRI offers relatively high accuracy in evaluating the extent of lymph node metastasis and parametrial involvement.MRI provides an objective basis for treatment options of endogenous cervical cancer.

Objective To investigate the treatment methods and prognostic factors of patient with cervical squamous cell carcinoma for FIGO stageⅠB2.Methods A total of 264 patients who were initial-treated and with intact-date in Cancer Hospital,Chinese Academy of Medical Sciences from May 1999 to May 2010 were retrospectively analyzed.The median age was 43 years(range from 21 to 60).57 patients initially treated with surgery(groupⅠ),193 patients underwent preoperative neoadjuvant chemotherapy(NACT)and(or)brachytherapy(groupⅡ)and 14 patients treated with concurrent chemoradiation(CCRT)(groupⅢ).Among the patients underwent operation,250 cases received type Ⅲ radical hysterectomy and pelvic lymphadenectomy and(or)para-aortic lymph node sampling.While 2 cases underwent pelvic lymphadenectomy as intraoperative lymph nodes were confirmed metastasis pathlogically,and changed to radical radiotherapy and concurrent chemotherapy.Results The 5-years disease-free survival and overall survival rates were 85%,89% respectively.There were statistically significant difference in disease-free survival between groupⅠ,Ⅱ,Ⅲ(P=0.001),which were 92.9%,85.2%,52.2%,respectively.Among the patients underwent surgery,the univariate analysis demonstrated that the number of lymph node dissection,number of metastatic lymph nodes and lymphovascular space invasion(LVSI)were significantly related to disease-free survival,while the depth of stromal invasion and grade of histological differentiation were not affect the prognosis.The positive ratio for LVSI in groupⅠ(35.1%)was higher than groupⅡ(12.4%),the difference had statistical significance(P=0.000),but the lymph node metastasis rate and the stromal invasion had no significant difference.In groupⅠ,71.9%patients(41/57)received adjuvant radiation combined with sensitive chemotherapy;In groupⅡ,The rate was 62.2%(120/193),which were lower than group I,but there was no significant difference.The group Ⅱ was classified into three groups:NACT,NACT plus brachytherapy and brachytherapy.In the subgroup analysis,there were no significant difference in lymph node metastasis,deep stromal invasion and positive ratio for LVSI between three groups.Conclusions The 5-years disease-free survival and overall survival rate for cervical squamous carcinoma of stage ⅠB2 were up to 85% and 89%.The disease-free survival for patients who were treated with preoperative chemotherapy and(or)radiotherapy plus radical surgery and direct operation,were better than patients received CCRT.The number of nodal metastases and LVSI affect the prognosis significantly.

OBJECTIVE:To investigate the efficacy and toxicity of neoadjuvant chemotherapy with paclitaxel and carboplatin or cisplatin for patients with locally advanced cervical cancer.METHODS:A total of 70 patients with locally advanced cervical cancer were treated with neoadjuvant chemotherapy with paclitaxel and carboplatin or cisplatin in our department from July 2007 to May 2010. The stage distribution among the patients included 45 stage IB2, 21 stage IIa, and 4 stage IIb. Of the 70 patients, 6 were G1, 26 were G2, 32 were G3, and the rest 6 patients were not histologically classified. Sixty-five patients had squamous cell carcinoma, 3 had adenocarcinoma, and 2 patients had adenosquamous cell carcinoma. The clinicopathological parameters were analyzed, and their impact on tumor response were investigated.RESULTS:Of the 70 patients, 14 (20.0%) showed a complete response, 37 (52.9%) had a partial response to chemotherapy, making an overall response rate of 72.9%. Sixty-eight (95.7%) patients underwent surgery, and among them 12 (17.1%) pathological CR were identified. Eleven (16.2%) patients were found to have lymph node metastasis after surgery. Response rates of stage Ib2 and IIa patients were 73.7% and 52.3%, respectively, P<0.05. Patients with SCC exhibited a better response rate than patients with adenocarcinoma and adenosquamous cell carcinoma (73.8% vs. 60.0%). Initial tumor volume, histological classification and cycles of neoadjuvant chemotherapy were not significantly correlated with the response rate.CONCLUSION:Paclitaxel and carboplatin or cisplatin regimen is a promising therapy with definite short-term efficacy, can improve the resection rate with tolerable side effects, and is an applicable option of treatment for patients with locally advanced cervical cancer in the neoadjuvant setting.

目的探讨贝伐单抗(BEV)与化疗联合治疗复发性卵巢癌的疗效、无进展生存时间和毒副反应。方法对采用BEV联合化疗治疗的18例复发性卵巢癌的有效率、无进展生存时间及毒性反应进行回顾性分析。给予患者BEV7.5mg/kg,同时与化疗药联合应用,每三周一次,至少治疗2个周期后评价疗效和1个周期后评价毒性。结果 18例复发性卵巢癌(除1例铂敏感型外)均为耐药/难治性患者,BEV治疗的中位周期数为4个。3例(16.7%)患者获得肿瘤完全缓解(CR),12例(66.7%)部分缓解(PR),总有效(CR+PR)率达83.3%。稳定(SD)患者2例(11.1%),仅1例患者(5.6%)为肿瘤进展(PD)。总临床获益率为94.4%。中位无进展生存时间7个月,有78.0%的患者无进展生存时间超过6个月。白细胞减少是最常见的毒副反应,3～4级仅占22.2%。总的3～4级毒性反应为33.3%。结论 BEV联合化疗治疗复发性卵巢癌有效率高,毒性反应小,有望成为治疗复发性(尤其复发耐药性)卵巢癌的安全、有效候选方案。

妇科恶性肿瘤包括子宫颈癌(CaCx)、子宫内膜癌(EMC)、卵巢癌(CaOV)(上皮来源、生殖细胞及性索间质来源)、外阴癌(CaVu)及阴道癌(CaVain)等,目前各疾病治疗手段选择及预后有所不同,现结合临床体会及文献报道介绍如下.

Objective To analyze the disease-free survival (DFS) and prognostic factors for stage Ⅰ_b cervical squamous cell carcinoma treated by radical hysterectomy. Methods From January 1999 to December 2005, a total of 206 patients with uterus cervical squamous cell carcinoma were retrospectively analyzed. All the patients were treated by type 3 hysterectomy and pelvic and/or para-aortic lymphadenectomy at Cancer Hospital, Chinese Academy of Medical Sciences. The diseases were stage Ⅰ_(B1) and Ⅰ_(B2)= in 103 patients each. Seventy-nine (76.7%) patients had preoperative radiotherapy and 111 (53. 9%) had postoperative adjuvant treatment (PosAT). Prognostic factors were analyzed using univariate model and multivariate Cox model. Results The follow-up rate was 92. 7%. 106 patients had following-up time of five years. The overall 5-year survival rate and the disease-free survival rate of stage Ⅰ_b,Ⅰ_(B1) and Ⅰ_(B2) were 96. 3% and 86. 8%, 100% and 94. 6%, 92. 2% and 77.9%, respectively. Univariate predictors of DFS included tumor size (FIGO stage, 77.9% : 94. 6% ; Χ~2 = 5. 58, P = 0. 018), lympho-vascular space involvement (LVSI, 74.6% : 89. 8% ; Χ~2 = 10. 44, P =0. 001), vaginal involvement (purely fornix involvement was not included disease, 50% : 87. 9% ; Χ~2 = 7.01,P = 0. 008), parametrial involvement (PI, Χ~2 = 17.69 ,P = 0. 000), and metastatic lymph nodes (LNM) > 2 (Χ~2 = 21.47, P = 0. 000) in stage Ⅰ_b disease, while LVSI (Χ~2 =6. 35,P =0. 012), PI (Χ~2 =90.00,P =0. 000) and LNM >2(Χ~2 =26. 27,P = 0. 000) in stage Ⅰ_(B1) disease, LVSI (Χ~2=10. 12,P =0. 001), cervical canal involvement (Χ~2 =4. 60,P = 0.032), vaginal involvement (Χ~2 =5.87,P=0.015), PI (Χ~2 =4.78,P=0.029) and LNM >2(Χ~2= 6. 72, P = 0. 010) in stage Ⅰ_(B2) disease. In multivariate analysis, FIGO stage (Χ~2 = 4. 73 ,P =0. 030), LVSI (Χ~2 = 9. 81, P = 0. 002), and LNM > 2 (Χ~2 = 6. 30, P = 0. 012) were significantly associated with DFS in stage Ⅰ_b, while LVSI (Χ~2 = 6. 38, P = O. 012) and LNM > 2 (Χ~2 = 3.92, P = 0. 048) were significantly associated with DFS in stage Ⅰ_(B2)-Conclusions LVSI is an important prognostic factor for stage Ⅰ_(B1) cervical cancer. PosAT reduces the recurrences in stage Ⅰ_(B2) desease. When PosAT is needed, preoperative radiotherapy can not improve DFS. PosAT should not be commonly used for stage Ⅰ_(B1) disease with only deep muscularis invasion.

目的:探讨中药、针灸联合治疗妇科恶性肿瘤行广泛子宫切除术后并发尿潴留的疗效.方法:对我院2年来妇科肿瘤患者行广泛子宫切除术后并发尿潴留进行临床分析.结果:238例术后有42例(占17.65%)不能排尿或能排尿但通而不畅,且残余尿>100mL,为尿潴留,经过中药黄芪茯苓汤(黄芪、茯苓、升麻、白术、车前草、红参等)及针刺关元、中极、三阴交等穴,治疗后均能顺利排尿.结论:中药及穴位注射治疗对妇科恶性肿瘤行广泛子宫切除术后并发尿潴留效果明显,有利于膀胱神经功能的恢复.

OBJECTIVETo explore the clinical-pathologic characteristics, treatment modalities and prognosis of patients with vaginal intraepithelial neoplasia (VAIN).METHODSThe clinical, pathologic and follow-up data of 20 cases with vaginal intraepithelial neoplasia treated primarily in Cancer Hospital of Chinese Academy of Medical Sciences from Jan. 1999 to Dec. 2007, were reviewed and analyzed retrospectively.RESULTSThere were not any of symptoms on diagnosis in all patients, and most of them (17 cases, 85%) were frequently detected VAIN for the abnormal pap smears or pelvic examination from cervical carcinoma patients and under the colposcopy as well as colposcopic biopsies. There were 3 cases (15%) with cervical cancer were diagnosed as VAIN during the postoperative follow up, while 17 cases (85%) of patients were accompanied with cervical cancer (12 cases) or cervical intraepithelial neoplasia (CIN, 5 cases) concomitantly or antecedently. Ninety percent of patients were diagnosed as VAIN III, 17 cases (85%) were mainly localized in the upper third of vagina, and 13 cases (65%) affected to the multiple vaginal walls. Thirteen cases were performed surgery, and 7 cases were treated by irradiation. The local control rate was achieved to 100% in all of patients. Three cases (included 1 post-irradiated and 2 post-operative) were relapsed after treatment, but still be controlled completely by radiotherapy or surgery.CONCLUSIONSVAIN was difficult to be diagnosed independently, which was frequently accompanied by cervical cancer or CIN, significantly localized in the upper third of vagina involving the multiple walls of vagina, and treated synchronously with cervical carcinoma and CIN accompanying. Surgery and radiotherapy was equally effective to control VAIN, and then follow-up post-treatment should be closely to detect, diagnose and treat recurrent VAIN as soon as possible after treatment.

OBJECTIVE:To explore the survival and prognostic factors for patients with advanced stage endometrial carcinoma,and identify the prognostic markers of advanced stage endometrial carcinoma.METHODS:Eighty-one patients with advanced stage endometrial carcinoma who were primarily operated in our hospital were analyzed retrospectively,and the correlation of the five-year survival rate was evaluated with the age,FIGO stage,tumor grade,the depth of myometrial invasion,peritoneal washing or ascites cytology,serum CA125 of pretreatment,the diameter of postoperative residual tumor and postoperative adjuvant therapy by the Kaplan-Meier method and Log-rank test,and the multivariables was analyzed by Cox proportional hazard models.RESULTS:The overall 5-year survival rate was 54.3% for 81 patients with advanced stage endometrial carcinoma.FIGO stage(χ2=37.419,P=0.000),the tumor grade(χ2=13.536,P=0.001),the depth of myometrial invasion(χ2=11.641,P=0.009) and the postoperative adjuvant therapy(χ2=19.102,P=0.000) were significantly correlated with the 5-year survival of advanced stage endometrial carcinoma by univariate analysis.However,the multivariate analysis revealed only FIGO stage was significantly associated with the prognosis of advanced stage endometrial carcinoma,χ2=9.32,P=0.002.CONCLUSION:The prognosis is poor for advanced stage endometrial carcinoma,and FIGO stage is a significant prognostic factor and independently affects on the survival of advanced stage endometrial carcinoma.

目前,国内外对复发性卵巢癌没有统一的定义,一般指卵巢癌患者经过肿瘤细胞减灭术和术后化疗后肿瘤未控或停药一段时间后肿瘤复发或转移称之为复发性卵巢癌.根据临床停药的间隔时间,将复发性的卵巢癌分为:铂敏感型(停药6或12个月后复发),进一步将停药6～12个月复发称为一般敏感型,停药12个月后复发为极敏感型;停药6个月内复发为铂耐药型,并将其分为难治性(停药3个月内复发或治疗时进展)及持续性(停药3～6个月复发)[1].

Objective:To explore the diagnosis,treatment and prognosis of the Ovarian Non-Hodgkin's Lymphoma (NHL). Methods:From October 1995 to August 2005, 11 Patients had received therapy as surgery, radiotherapy and chemotherapy . Regimens of chemotherapy with CHOP, mBACOD, MACOP as well as ProMACE-CytaBOM and so on. 3 Patients was had gotten super high dose chemotherapy after bone marrow transplantation. Results:One patient was refused to receive chemotherapy and miss following up after operation, The other obtained 12 months diseases free survival when was given super high dose chemotherapy; 9 patients had been followed up till death, The median survival time was 13 months (range 5～26 months). Conclusion:The prognosis of Ovarian NHL is very grievous, The combined modality therapy should be taken.

近20年来美国的子宫颈癌发病率几乎下降近1/3,2006年估计全年发患者数为10 370例,而同年死于子宫颈癌者约3710例,在世界范围内,每年子宫颈癌发病510000例,死亡288 000例,是仅次于乳腺癌发病率而居第二位,近3/4的病例发生在发展中国家.

复发性妇科恶性肿瘤的再手术治疗问题是一个极为复杂的问题,与以下几方面因素有关:①肿瘤复发的部位及数目;②以前接受治疗的情况;③重要脏器是否受累;④能否完全切净肿瘤;⑤是否还有较为有效的辅助治疗.一般来说,妇科恶性肿瘤包括以下几种类型.

Objective: To assess the correlation between the sensitivity of some chemotherapeutical agents in vitro and the effective rate of clinical treatment. Methods: Seven chemotherapeutical agents and 6 combined regimens were used to test the inhibition ratio for 70 cases with ovarian epithelial carcinoma using MTT assay in vitro. Results: The effective rates for the agents and combined regimens were 6.25%-51.43% and 10.00%-35.00%, respectively in 7 chemotherapeutical agents and 6 combined regimens, such as PTX (51.45%), TXT (20.29%), DDP (18.57%), TPT (11.63%), ADM (11.43%) and GEM(8.82%), as well as Vp16 (6.25%). The PTX(51.45%) was the most sensitive agent for ovarian epithelial carcinoma compared with other 6 agents, especially the last 4, with a statistical significance (P<0.05) and TPT+PTX+DDP(35.00%), 8PTX+DDP(30.00%) as well as 4 others. TXT+DDP (20.59%) TPT+DDP (17.65%); GEM+DDP (11.76%), Vp16+ADM (10.00%). In the study, there was no correlation between the pharmaceutical inhibition ratio and the fact whether or not the drug has been used. The in vivo, sensitive and drug-fast coincident rate was 72.86% (51/70) and the discrepancy was 27.14%(19/70). There was a statistical significance (P<0.05) between the overall coincidence and the discrepancy. Conclusion: The MTT assay in vitro has a referenced value for the individualized regimens on ovarian epithelioma and can, to some extent, direct the clinical medication.

Objective To evaluate the clinicopathological features of benign tumors of the fallopian tube.Methods There were five cases suffered from benign tumors of the fallopian tube admitted in our hospital between 1992 to 2003.Their clinical and pathological data were retrospectively studied.Results They were found in patients aged 26.8-50.1(average 40.7)years.All five patients had regular menopauses and no infertility.There was only one patient with symptom of pelvic mass.All patients were found with adnexal masses of 6-10 cm in diameter when pelvic examination.Ultrasonography showed adnexal masses of 2-10 cm in diameter in 4 cases.Their serum CA125 level were normal.Preoperative diagnoses were pelvic masses in 4 cases( 3 cases with ovarian tumors),but none was diagnosed with benign tumor of the fallopian tube.Three patients were found with tumors of fallopian tube and diagnosed with benign tumors of the fallopian tube by frozen section analysis in operation.In the other two patients with myomas of the uterus one case was found with bilateral enlarged fallopian tubes and one with normal fallopian tubes.The benign tumors of the fallopian tube of 5 cases with were resected.By permanent histologic examination there were 3 adenofibromas,1 adenomatoid tumor and 1 bilateral myomas of fallopian tubes.All patients were followed from 3-year 6-month to 13-year 7-month and no abnormal sign was found.Conclusion Adenofibromas was the main histologic type of the fallopian tube in our group.There might be clinical symptoms and signs of pelvic masses in benign tumors of the fallopian tube,but most cases were diagnosed with ovarian tumors by mistake.And in operation benign tumors of the fallopian tube might not be diagnosed.The diagnoses could be sure by frozen section analysis in operation and permanent histologic examination.The benign tumors of the fallopian tube had good prognosis by resectomies of the tumor.

目的:探讨子宫内膜癌腹膜后淋巴结多点活检的临床意义.方法:对本院1990年1月～2000年12月初次手术时行腹膜后淋巴结活检的165例子宫内膜癌患者进行回顾性分析.比较各种临床病理因素的腹膜后淋巴结转移率,淋巴结转移与无转移及不同转移数目的5年生存率.结果:165例腹膜后淋巴结多点活检中,21例病理证实淋巴结转移,5年生存率23.81%,中位生存期30.20个月,与无淋巴结转移107例(随访5年以上),5年生存率66.36%,中位生存77.30个月,两者比较(P＜0.001).淋巴结转移≤3枚10例,5年生存率50.00%,中位生存42.10个月与淋巴结转移≥4枚11例,无5年生存,中位生存期21.30个月,两者相比(P＜0.001).经单因素分析,临床分期、组织类型、病理分级、肌层浸润深度、宫颈浸润、宫旁浸润及附件浸润、淋巴血管瘤栓与腹膜后淋巴结转移有关(P＜0.05),经多因素相关分析,此8个变量间比较,差异有显著性(P＜0.05).结论:腹膜后淋巴结多点活检能使手术病理分期更准确,是子宫内膜癌预后的重要因素之一,临床Ⅰ、Ⅱ期子宫内膜癌手术应常规行腹膜后淋巴结多点活检.

Objective:To analyze the clinical characteristic, treatment methods and prognostic factors of primary malignant melanoma of female genitalia. Methods:The clinical and pathological materials were systematic reviewed thirty patients of primary malignant melanoma of female genitalia from June 1991 to June 2001 in our hospital. Results:In the thirty patients of primary malignant melanoma of female genitalia,ten patients were survival more than two years account for 38.5%(10/26), four patients more than three years about 15.4%(4/26) and three patients more than five years approximately 11.5%(3/26). The median survival: the stages Ⅰ, Ⅱ(27.3 months, 29.1 months) compared with stages Ⅲ, Ⅳ(21.7 months, 15.3 months) have significant difference (P0.05). The position of vulva malignant melanoma (35.3 months) versus the position of vaginal (20.3 months) and cervix (17.6 months) malignant melanoma have significant difference (P0.05). The modality of surgery (27 months) compared with non-surgery (11.3 months) and the infiltrate depth of tumor less than (or equal) 4mm (53.2 months) versus the infiltrate depth of tumor more than 4mm (19.1 months) as well as non-lymph nodes metastasis (34.7 months) compared with lymph nodes metastasis (14.1 months) have very significant difference (P0.01).Conclusions:The malignant melanoma of female genitalia is a tumor of high virulence and poor prognosis. Surgery is the main treatment modality. The prognostic factors were influenced on by clinical stages, locality of tumor, infiltrate depth of tumor metastatic lymph nodes and treatment modality. Local recurrence and early distant metastasis are the prime factors of poor prognosis.